Alnylam Pharmaceuticals, Inc. (ALNY)
-NasdaqGS 27.44 
0.23(0.85%) May 17, 4:00PM EDT|After Hours
:
27.44 0.00 (0.00%) May 17, 4:32PM EDT
| Prev Close: | 27.21 |
|---|
| Open: | 27.78 |
|---|
| Bid: | 20.21 x 500 |
|---|
| Ask: | 33.00 x 200 |
|---|
| 1y Target Est: | 30.75 |
|---|
| Beta: | 1.79 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 27.04 - 27.89 |
|---|
| 52wk Range: | 9.78 - 28.68 |
|---|
| Volume: | 520,072 |
|---|
| Avg Vol (3m): | 441,722 |
|---|
| Market Cap: | 1.71B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.94 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Alnylam announces proof-of-concept data from RNAi programtheflyonthewall.com(Fri, May 17)
- Alnylam announces proof-of-concept data from RNAi programat theflyonthewall.com(Fri, May 17)
- InPlay: Alnylam Pharma presents key pre-clinical proof-of-concept data for ALN-AS1; RNAi therapeutics targeting ALAS-1 completely block production of toxic heme biosynthesis intermediates that cause symptoms and disease pathologyBriefing.com(Fri, May 17)
- Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinate Synthase-1 (ALAS-1) for the Treatment of PorphyriaBusiness Wire(Fri, May 17)
- Alnylam Pharmaceuticals' CEO Presents at 2013 Bank of America Merrill Lynch Health Care Conference (Transcript)at Seeking Alpha(Thu, May 16)
- Alnylam to Webcast Presentation at 2013 UBS Global Healthcare ConferenceBusiness Wire(Wed, May 15)
- ALNYLAM PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Tue, May 14)
- Alnylam to Webcast Presentation at 2013 Bank of America Merrill Lynch Health Care ConferenceBusiness Wire(Wed, May 8)
- ALNYLAM PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, May 7)
- Alnylam Narrows Loss, Sales FallZacks(Tue, May 7)
- Alnylam Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Mon, May 6)
- Alnylam takes smaller 1Q loss on lower costsAP(Mon, May 6)
- Alnylam Pharmaceuticals Earnings: Here’s Why Investors are Excited Nowat Wall St. Cheat Sheet(Mon, May 6)
- Alnylam Pharmaceuticals Reports First Quarter 2013 Financial ResultsBusiness Wire(Mon, May 6)
- ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsEDGAR Online(Mon, May 6)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 26.11 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.33 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.34 |
|---|
| Mean Recommendation*: | 2.1 |
|---|
| PEG Ratio (5 yr expected): | 3.10 |
|---|
Business Summary
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi).
View More